InnoCare Pharma Ltd. Class A 688428
SSE · China · Health Technology
CNY 29.11+0.23 (+0.80%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pharma valued at up to US$3.35b in research and licensing commitments. These combined FDA approvals and the US$3.35b InnoCare alliance deserve weighing against the rest of our Eli Lilly analysis. We have also...
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.